

## SphingoTec Issues Convertible Note Facility

**Hennigsdorf, Germany August 19, 2020** – Diagnostic company SphingoTec GmbH (SphingoTec) today announced that the Company has issued a non-brokered, unsecured convertible note facility amounting to EUR 5 million that was fully subscribed by current and new investors. The proceeds of the transaction will bridge to a larger financing round planned for later this year or early 2021 to fund the further growth of the company, in particular the commercialization of the company’s innovative diagnostic products for critical care in Europe, the required scale up of manufacturing capabilities and gaining access to the U.S. market.

### About SphingoTec

SphingoTec GmbH ( “SphingoTec”; Hennigsdorf near Berlin, Germany) develops and markets innovative in-vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies. SphingoTec's proprietary biomarker portfolio includes Bioactive Adrenomedullin (bio-ADM<sup>®</sup>), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid<sup>®</sup>), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardiac depression. IVD tests for SphingoTec’s proprietary biomarkers are made available as sphingotest<sup>®</sup> microtiterplate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by SphingoTec’s subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of established and commonly used tests for acute and critical care.